

# CORPORATE FACT SHEET



As of June 30, 2010

## OFFICES

45 Moulton Street  
Cambridge, MA 02138  
e-mail: [info@curis.com](mailto:info@curis.com)  
URL: [www.curis.com](http://www.curis.com)  
Phone: 617-503-6500  
Fax: 617-503-6501

## BUSINESS

Drug Development with a small molecule cancer focus

## FOUNDED

2000

## OWNERSHIP

Publicly traded on NASDAQ Global Market ("CRIS")

## SHARES

75.6 million basic shares outstanding  
89.3 fully diluted shares outstanding

## EMPLOYEES

Approximately 40

## COLLABORATIONS

- (1) Genentech: Hedgehog Antagonist (Cancer)
- (2) Genentech: Wnt signaling pathway (Cancer)
- (3) Debiopharm: Hsp90 (Cancer)

## TRANSFER AGENT

BNY Mellon Shareowner Services  
P.O. Box 358015  
Pittsburgh, PA 15252-8015  
URL: [www.bnymellon.com/shareowner/isd](http://www.bnymellon.com/shareowner/isd)  
Phone: 877-810-2248

Please see Curis' Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings that we periodically make with the Securities & Exchange Commission for additional information on the company and its status based on filing date.

## MANAGEMENT TEAM

Daniel R. Passeri, President and  
Chief Executive Officer

Michael P. Gray, Chief Operating and  
Chief Financial Officer

Changgeng Qian, Ph.D., M.D., Senior Vice President,  
Discovery and Preclinical Development

Mitchell Keegan, Ph.D., Vice President, Drug Development

Mark W. Noel, Vice President, Technology Management and  
Intellectual Property

## BOARD OF DIRECTORS

James R. McNab, Jr. - Chairman of the Board

Susan B. Bayh

Joseph M. Davie, Ph.D., M.D.

Martyn D. Greenacre

Kenneth I Kaitin, Ph.D.

Daniel R. Passeri

Marc Rubin, M.D.

James R. Tobin

Michael Gray  
COO and CFO

Curis, Inc.  
45 Moulton Street  
Cambridge, MA 02138

Tel: 617.503.6500  
Fax: 617.503.6501  
[www.curis.com](http://www.curis.com)